Oral Hygiene Management of Hematologic Patients Undergoing Auto-transplantation
1 other identifier
observational
35
1 country
1
Brief Summary
This study assessed the effectiveness of a preventive protocol that included oral hygiene measures, patient education, and motivational strategies in individuals eligible for hematopoietic stem cell transplantation (HSCT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 9, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 29, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2024
CompletedFirst Submitted
Initial submission to the registry
December 18, 2024
CompletedFirst Posted
Study publicly available on registry
January 1, 2025
CompletedJanuary 1, 2025
December 1, 2024
9 months
December 18, 2024
December 24, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
PPD
probing pocket depth (PPD) was measured as the distance from the free gingival margin to the bottom of the pocket by inserting a periodontal probe parallel to the longitudinal axis of the tooth using a periodontal probe (UNC 15, Hu-Friedy, Chicago, IL, USA) and a calibrated pressure of 0.3 N. All measurements were rounded to the nearest millimetre.
measured at enrolment (T0) and 9 days after engraftment (T1)
FMBS
Full Mouth Bleeding Score (FMBS) was measured dichotomously after periodontal probing. The mean bleeding score was indicated as percentage of sites detected positive for bleeding on the total number of sites
measured at enrolment (T0) and 9 days after engraftment (T1)
FMPS
Full Mouth Plaque Score (FMPS) was assessed the presence or absence of plaque on each tooth surface. The presence of plaque was evaluated as 1, while the absence as 0, on 6 sites per tooth (distobuccal, buccal, mesiobuccal, distolingual, lingual, mesiolingual). Mean plaque score was indicated as percentage of sites found positive for the presence of plaque on the total number of sites
measured at enrolment (T0) and 9 days after engraftment (T1)
CI
Calculus Index was measured using a probe and considering supragingival and subgingival calculus separately, with score 0 assigned in the absence of calculus and score 3 assigned to supragingival calculus exceeding two-thirds of the crown and/or continuous bands of subgingival calculus
measured at enrolment (T0) and 9 days after engraftment (T1)
PRESENCE OF MUCOSITIS
Presence of mucositis was evaluated as the presence of mucosal erythema or ulceration for 8 oral sites and assigning a score from 0 (normal oral mucosa) to 5 (\>3 sites of ulceration).
measured 9 days after engraftment (T1)
Interventions
the patient underwent a professional oral hygiene session before starting chemotherapy, as part of the routine pre-transplant procedure. Patients then received oral hygiene instructions.
Eligibility Criteria
patients undergoing autologous hematopoietic stem cell transplantation (HSCT) for hematologic diseases. The study included patients treated at the Hematology Unit of Pisa University Hospital. Participants were selected based on their eligibility for HSCT and their consent to participate in the study
You may qualify if:
- male or female patients
- aged 18-75 years
- patients scheduled for HSCT
- acceptance of study participation
- compliance to follow-up
You may not qualify if:
- \- denial of the consent to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University Hospital of Pisa
Pisa, Italy
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Researcher at the Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine of the University of Pisa, Principal Investigator
Study Record Dates
First Submitted
December 18, 2024
First Posted
January 1, 2025
Study Start
January 9, 2023
Primary Completion
September 29, 2023
Study Completion
May 31, 2024
Last Updated
January 1, 2025
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share